Identifying biomarkers in autoimmune and inflammatory diseases
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
This study is trying to find specific markers in the blood of people with autoimmune diseases to help tailor their treatment and track how well it works.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, France) |
| Trial ID | NCT05383339 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify cytokine and lymphocyte biomarkers in patients with autoimmune diseases, systemic vasculitis, and autoinflammatory diseases. By collecting biological samples as part of routine patient care, the study seeks to develop prognostic biomarkers that can personalize treatment and follow-up for these patients. The research is conducted at a certified national reference center, focusing on understanding the immunological profiles that predict disease activity and treatment response.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older diagnosed with specific autoimmune systemic diseases, systemic vasculitis, or autoinflammatory diseases.
Not a fit: Patients with conditions outside the defined autoimmune and inflammatory diseases or those belonging to vulnerable populations may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with autoimmune and inflammatory diseases.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for autoimmune diseases, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of 18 years of age or older * Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following: * Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis * Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura) * Buerger's disease (obliterating thromboangitis) * Granulomatosis and sarcoidosis * Uveitis * Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis * Recurrent fevers and unexplained inflammatory syndromes * Inflammatory amyloidosis * Patients affiliated to French social security Exclusion Criteria: * Vulnerable populations: * Persons deprived of liberty by judicial or administrative decision; * Persons receiving psychiatric care without their consent; * Adult subject to a legal protection measure (guardianship, curatorship); * Persons unable to give their consent.
Where this trial is running
Paris, France
- Département de Médecine Interne et Immunologie Clinique (DMIIC), Hôpital Pitié-Salpêtrière — Paris, France, France (Recruiting)
Study contacts
- Principal investigator: David Saadoun, Professor — Assistance Publique - Hôpitaux de Paris
- Study coordinator: David Saadoun, Professor
- Email: david.saadoun@aphp.fr
- Phone: +33142161051
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.